Contact
searchSearch
HMP Global
Login

BREAST CANCER

News
Real-World Practice Patterns for First-Line Treatment of Metastatic Breast Cancer
06/29/2021
Study results show substantial variation in treatment selection and costs for first-line treatment of patients with metastatic breast cancer in Washington State.
Study results show substantial variation in treatment selection and costs for first-line treatment of patients with metastatic breast cancer in Washington State.
Study results show substantial...
06/29/2021
Journal of Clinical Pathways
Conference Coverage
Treatment Patterns Following First-Line Therapy for HER2-Positive Metastatic Breast Cancer
06/07/2021
A study exploring practice patterns in HER2-positive breast cancer in the United States found that the most common second-line treatment following first-line pertuzumab plus trastuzumab were T-DM1-based regimens.
A study exploring practice patterns in HER2-positive breast cancer in the United States found that the most common second-line treatment following first-line pertuzumab plus trastuzumab were T-DM1-based regimens.
A study exploring practice...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Outcomes of Patients Receiving Alpelisib for PIK3CA-Mutated Breast Cancer
06/07/2021
Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world PFS compared with those who receive fulvestrant alone.
Patients with breast cancer and PIK3CA mutations who receive alpelisib plus fulvestrant have longer real-world PFS compared with those who receive fulvestrant alone.
Patients with breast cancer and...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for Early Breast Cancer
06/07/2021
Neoadjuvant pertuzumab, trastuzumab, and hyaluronidase-zzxf plus chemotherapy is expected to be cost-effective vs neoadjuvant pertuzumab and trastuzumab plus chemotherapy for patients with high-risk HER2-positive early breast cancer.
Neoadjuvant pertuzumab, trastuzumab, and hyaluronidase-zzxf plus chemotherapy is expected to be cost-effective vs neoadjuvant pertuzumab and trastuzumab plus chemotherapy for patients with high-risk HER2-positive early breast cancer.
Neoadjuvant pertuzumab,...
06/07/2021
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use